Intravaginal iridium-192 in the management of embryonal rhabdomyosarcoma.
Three patients with vaginal rhabdomyosarcoma and residual vaginal disease following surgery and chemotherapy have been treated using high dose irradiation with vaginal moulds loaded with iridium-192. These patients remain well and disease-free seven years, 30 months and 18 months after their initial presentations. This paper describes a technique for local vaginal irradiation with individualized vaginal moulds made using a rapid-setting silastic foam impression and loaded with a single plane of iridium wires. Details of the dosimetry are also included.
O'Connell
M E
ME
Department of Radiotherapy, Royal Marsden Hospital, Sutton, Surrey, UK.
Hoskin
P J
PJ
Mayles
W P
WP
McElwain
T J
TJ
Barrett
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004867:Equipment Design; D005260:Female; D006801:Humans; D007223:Infant; D007496:Iridium Radioisotopes / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D014621:Vagina / Q000528:radiation effects*; D014625:Vaginal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D014750:Vincristine / Q000008:administration & dosage
D007496:Iridium Radioisotopes; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide